



## Diffusion Tensor Imaging Study of Olfactory Identification Deficit in Patients With Mild Cognitive Impairment

Yongjia Shao<sup>1†</sup>, Zijian Wang<sup>2†</sup>, Bin Ji<sup>1†</sup>, Hang Qi<sup>1</sup>, Shangci Hao<sup>1</sup>, Gang Li<sup>3</sup>, Yue Zhang<sup>3\*</sup> and Qian Xi<sup>1\*</sup>

<sup>1</sup> Department of Radiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, <sup>2</sup> School of Computer Science and Technology, Donghua University, Shanghai, China, <sup>3</sup> Department of Neurology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

### **OPEN ACCESS**

**Edited by:** Ping Wu, Fudan University, China

### Reviewed by:

Kenji Toba, Tokyo Metropolitan Institute of Gerontology, Japan Yuxin Li, Fudan University, China Jerzy Walecki, Medical University of Warsaw, Poland

#### \*Correspondence:

Yue Zhang dyuezhang@126.com Qian Xi 96125007@sina.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

Received: 27 August 2021 Accepted: 01 November 2021 Published: 23 November 2021

#### Citation:

Shao Y, Wang Z, Ji B, Qi H, Hao S, Li G, Zhang Y and Xi Q (2021) Diffusion Tensor Imaging Study of Olfactory Identification Deficit in Patients With Mild Cognitive Impairment. Front. Aging Neurosci. 13:765432. doi: 10.3389/fnagi.2021.765432 **Objective:** To explore the relationship between white matter changes and olfactory ability among patients with mild cognitive impairment (MCI) and to develop a tool to predict the development of Alzheimer's disease among patients with MCI.

**Methods:** The Montreal Cognitive Assessment (MoCA) was used for cognitive assessments, and the 70% isopropanol test paper was used to evaluate olfactory function. Tract-based spatial statistics, based on the diffusion tensor imaging technology, were used to obtain relevant parameters, and behavioral and imaging results were compared between patients with MCI (n = 36) and healthy older adults (n = 32).

**Results:** The olfactory ability of MCI patients was lower overall, which was positively correlated with the MoCA score. Fractional anisotropy (FA) changes significantly of all parameters. Lower FA regions were mainly located in the corpus callosum, the orbitofrontal gyrus, and the left occipital lobe. The olfactory score was significantly correlated with the FA value of the orbitofrontal gyrus. Fibrous connections in several brain regions, such as the entorhinal cortex, were stronger in patients with MCI.

**Conclusion:** The olfactory ability of MCI patients in our group was positively correlated with the neuropsychological scale results. Impairment in olfactory function was superior to memory deficits for predicting cognitive decline among cognitively intact participants. The fibrous connections in several brain regions, such as the entorhinal cortex, were higher in patients with MCI, which suggested that there may be a compensatory mechanism in the olfactory pathway in MCI patients. The decline in olfactory function may be a significant and useful indicator of neuropathological changes in MCI patients and an effective marker for the development of cognitive decline and dementia.

Keywords: diffusion tensor imaging, tract-based spatial statistics, mild cognitive impairment, Alzheimer's disease, olfactory dysfunction

1

### INTRODUCTION

Alzheimer's disease (AD), which is characterized by latent and progressive cognitive decline, is the most common etiology for dementia and is recognized as an urgent concern that has significant implications for both individuals and society (Lane et al., 2018). Mild cognitive impairment (MCI), which is considered a transitional state between normal aging and dementia, has a conversion range of 8-15% per year (Shu et al., 2021). In line with recommendations form the National Institute on Aging-Alzheimers's Association workgroups, we use the term "MCI due to AD" to refer to the symptomatic predementia phase of AD, which suggests that MCI is a critical stage for preventive treatment for dementia (Albert et al., 2011). Therefore, there is significant interest in developing a sensitive, specific, and non-invasive method for the early prediction of MCI before progression to AD. At present, neuropsychological tests and neuroimaging technology, such as positron emission tomography (PET), cerebrospinal fluid (CSF) measurements, and magnetic resonance imaging (MRI), are commonly used for early diagnosis of MCI (Jung et al., 2019). However, neuropsychological tests are subjective and are easily affected by factors, such as subject's mood, mental status, and educational background. Furthermore, the high cost of PET and the invasive nature of obtaining CSF limit their utility. Neuroimaging methods have proliferated in recent years; among them, diffusion-tensor imaging (DTI) is a noninvasive neuroimaging modality used to evaluate the structure of white matter in the brain, which is currently the only way to map white matter fiber architecture in brain tissue. Fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (DR), and axial diffusivity (DA; Georgiopoulos et al., 2017) are the most commonly used DTI metrics. Among these, FA and MD are most frequently reported. In DTI, the displacement of water molecules is used to measure white matter tract integrity. FA assesses the degree of directionality of water diffusion, whereas MD measures the mean water diffusion rate.

The olfactory center of the brain is composed of the primary (POC) and secondary olfactory cortices (SOC). The POC plays an important role in olfactory detection and has a complex structure that mainly comprises the entorhinal cortex (EC), amygdala, and piriform cortex (Kjelvik et al., 2020). The SOC is involved in olfactory recognition and mainly includes the hippocampus, hypothalamus, orbitofrontal gyrus, striatum, and corpus callosum. Among them, the orbitofrontal gyrus is the highest olfactory center, that determines the pleasure and familiarity of odors (Zhao et al., 2016). The olfactory pathway not only overlaps with hippocampus, the typical lesion site of AD, but also is involved in early pathological changes of AD (Marin et al., 2018). In line with a recent study, AD-related pathological alterations first resulted in synaptic neurodegeneration and then neuronal loss, it found no significant neuronal loss in the EC was detectable in cognitively normal subjects, by contrast, there was a very severe neuronal loss in the EC even in very mild AD cases (Li et al., 2021). The results highlighted the EC maybe helpful for predicting the pre-symptomatic and very mild stages of AD, therefore, olfactory function assessment provides

the possibility for early recognition of cognitive dysfunction. Numerous recent studies applied neuroimaging modality to identify a clinical marker for predicting the preclinical AD, a study verified a strong correlation between olfactory impairment and white matter damage (Woodward et al., 2017). Some have also found, compared with cognitively normal controls (NC), patients with MCI were shown to have lower FA and higher MD in the hippocampus, EC, medial temporal lobe, and corpus callosum (Knight et al., 2019), which overlap with several of the olfactory functional areas described above. In addition, one study reported patients with more severe cognitive dysfunction had worse olfactory function (Yoo et al., 2018). All of these findings suggest that olfactory identification (OI) is a significant factor for predicting the risk of MCI-to-AD transition (Devanand, 2016). However, further research is needed to identify a visual indicator for predicting the development of AD in MCI patients with OI impairment.

In this prospective study, DTI and tract-based-spatialstatistics (TBSS) were used to conduct a cross-sectional analysis of white matter microstructural changes in MCI patients and NC to explore the relationship between white matter changes and olfactory ability in patients with MCI and to develop a reliable method for improving diagnoses and reducing underdiagnoses of MCI and dementia.

### MATERIALS AND METHODS

### **Study Participants**

Sixty-eight subjects (36 MCI and 32 NC) were recruited from the Shanghai Jinguang community from March 2017 to December 2019. All patients were recruited by the Neurology Department of Shanghai East Hospital (Southern Branch) after they underwent neuropsychological tests. The study was reviewed and approved by the Ethics Review Committee of Shanghai East Hospital, and written informed consent was obtained from all participants.

The Mini-Mental State Examination (MMSE) is the most widely used screening scale owing to its speed and ease of administration. However, its sensitivity in identifying patients with MCI, AD and healthy people is relatively low (Albert et al., 2011). While, the Montreal Cognitive Assessment (MoCA) covers a wider range of cognitive domains, including attention and concentration, executive function, memory, language, visualspatial structure skills, abstract thinking, computation and orientation, therefore, it has superior sensitivity and specificity to the MMSE in predicting cognitive decline (Lu et al., 2011).

Inclusion criteria for MCI patients were the following: (1) a subjective complaint of mild cognitive decline by the patient, preferably confirmed by an insider; (2) minimal effect of working and living independently and handling complex tasks; (3) objective evidence of memory loss, with an MMSE score  $\leq 27$  and  $\geq 24$ ; (4) absence of dementia, with a MoCA score  $\leq 24$  (illiterate group  $\leq 13$  points, primary school group  $\leq 19$  points, middle school and above group  $\leq 24$  points), based on MoCA for detecting MCI in Chinese older adults (Lu et al., 2011).

Inclusion criteria for NC were the following: (1) independent behavioral ability, no cognitive or memory impairment, no

depression, and no organic nervous system diseases; and (2) a MoCA score > 24 (Lu et al., 2011).

Exclusion criteria were the following: (1) history of nervous system tumor, craniocerebral surgery, stroke, or brain trauma; (2) serious medical diseases, such as organ dysfunction, autoimmune diseases, blood system diseases, anemia, and tumor; (3) unable to cooperate with examination because of a mental disorder, speech confusion, or severe hearing impairment; and (4) other neurodegenerative diseases causing cognitive impairment, such as bipolar disorder, mania, schizophrenia, epilepsy, PD, and multiple sclerosis.

### **Olfactory Identification Test**

The most commonly used odor identification test is the University of Pennsylvania Smell Identification Test (UPSIT), however, it takes too long to administer by using 40 scents. Furthermore, too much odor identification can be affected by differences in region, culture, and individual experiences, so it is complicated to use as a screening test for the elderly (Kim et al., 2020, 2021). The "Sniffin' Sticks" Test (SST) is another widely used odor test, but its applicability is limited because of the high cost and the regional-cultural differentiation of odor recognition (Demir et al., 2021). Therefore, all of our subjects underwent the Alcohol Sniff Test, which is a simple, rapid, and reliable measure of olfaction, it takes less than 5 min to administer, has good testretest reliability and can be used cross-culturally, which is easy to use in the elderly (Davidson et al., 1998). In a quiet, ventilated, and private environment, subjects kept their eyes and mouth closed while the researcher placed a soft ruler under the subject's nose with the proximal end of the ruler perpendicular to the tip of the nose. The isopropyl alcohol (70 g/100 ml) test paper was placed under the subject's nose at the 30 cm mark of the soft ruler. The subject was then instructed to take a deep breath while the researcher simultaneously moved the test paper in 1 cm increments up the ruler with each breath until the subject could smell an isopropyl alcohol odor. The test was repeated four times, and the average distance was calculated. The score was based on the distance from the tip of the nose to the test paper, which indicated anosmia (average distance <10 cm), hyposmia (10 cm  $\leq$ average distance  $\leq$ 15 cm), or normal smell (average distance >15 cm) (Ashwin et al., 2014).

### **Magnetic Resonance Imaging**

All participants underwent a DTI scan on an M750w 3.0T GE Signa MRI system (GE Healthcare, American) with a 32channel head and neck coil. During scanning, all subjects lay in a supine position with their head positioned in the center of the coil, and earplugs were placed in their ears to reduce scanner noise. Participants were asked to minimize head movements as much as possible. T1-weighted threedimensional (3D-T1), axial T2-weighted, and fluid-attenuated inversion recovery images constituted the structural imaging, which was used to exclude abnormalities other than atrophy or white matter degeneration. 3D-T1 images were acquired using a fast-spoiled gradient recalled echo sequence [repetition time (TR) = 8.5 ms, echo time [TE] = 3.2 ms, field of view [FOV] =  $256 \times 256$  mm, slice thickness = 1 mm]. In addition, diffusion-weighted imaging (DWI) and DTI were acquired simultaneously. The DWI sequence parameters were: TR = 13700 ms, TE = 85 ms, FOV = 224 × 224 mm, slice thickness = 2 mm. The DTI sequence parameters were: TR = 13701 ms, TE = 114 ms, FOV = 224 × 224 mm, slice thickness = 2 mm, diffusion coefficient b = 1000 s/mm<sup>2</sup>, 64 diffusion-sensitive gradients, one b = 0 s/mm<sup>2</sup>, and 70 continuous slices in each gradient direction.

### **Imaging Processing**

3D-T1 images were reviewed by two experienced radiologists to check for any morphological abnormalities. The regions of interest (ROIs) were determined jointly by neurologists and radiologists who had no knowledge of patient information, including the hippocampus, the corpus callosum, the orbitofrontal gyrus and the left inferior occipital gyrus. Post-processing of DTI data was performed using the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library version 5.0<sup>1</sup>, which contains TBSS and FMRIB's diffusion toolbox (FDT). Original DTI images were corrected for head movement and eddy current distortions, which was followed by brain extraction to eliminate non-brain tissue and brain mask generation to ensure inclusion of the ventral surface of the forebrain using the Brain Extraction Tool (BET). Subsequently, commonly used DTI metrics were estimated, derived and calculated using FDT, such as FA, MD, DA, and DR, which applies a diffusion tensor model to describe fibrous structural characteristics that indicate white matter microdamage (Tae et al., 2018). Then, we used the abnormal area based on the whole-brain TBSS analysis results as the seed region to perform probabilistic diffusion tractography with a probability of over 90%, and the specific process mainly includes tracer modeling, image registration and tracer analysis.

<sup>1</sup>https://fsl.fmrib.ox.ac.uk/fsl/fslwiki

**TABLE 1** | Demographic information of participants.

Group	MCI (n = 36)		NC (n = 32)		Test	
	Mean	SD	Mean	SD	t	p
Age (year)	67.794	6.3331	68.810	5.5463	-0.6050	0.548
Education background (year)	9.2060	2.4093	9.1430	2.0071	0.1000	0.921
OI score	10.118	3.8672	17.143	2.3084	-7.5220	< 0.001
MoCA score	17.412	6.2091	27.000	1.4491	-6.9380	< 0.001
	Ν	Female (%)	Ν	Female (%)	F	X <sup>2</sup>
Sex ratio	36.000	58.300	32.000	42.900	1.0000	0.1710

TABLE 2 Comparison of behavioral score between MCI patients and NCs.

	MCI (n = 36)	NC ( <i>n</i> = 32)	Р
OI score	$10.12 \pm 3.87$	$17.14 \pm 2.31$	<0.010
MoCA score	$17.41 \pm 6.21$	$27.00\pm1.45$	< 0.010

 TABLE 3 | Correlation between MoCA score and OI score.

		MoCA score	OI score
MoCA score	r	1.000	0.682
	р	-	< 0.001
OI score	r	0.682	1.000
	р	<0.001	-

### **Statistical Analysis**

Statistical calculations were performed with the Statistical Package for the Social Sciences version 23.0 IBM. Means  $\pm$  standard deviations (SD) were used to express measurement data, which were assessed for normality test prior to statistical analysis, and then the two independent sample *t*-tests were carried out according to the normality test result; whereas chi-squared tests were used for enumeration data. The FSL-Randomize function was used to extract the average values of FA, DA, DR, and MD of the whole brain in the experimental and control group, and then statistical tests were performed on the average values of above DTI metrics, and inter- and intra-group statistical analyses of DTI data for ROIs were performed. In addition, correlation analyses were conducted between the behavioral indicators and olfactory test values, as well as between the behavioral and the imaging indicators. At the same time, we make the receiver operating characteristic (ROC) curve to reveal the correlation between sensitivity and specificity.

### RESULTS

## Clinical Characteristics of the Study Cohort

Results showed that there were no significant differences in sex ratio, age, or educational background between the groups (p > 0.05, **Table 1**). However, OI and MoCA scores were significantly different between the experimental and control groups (p < 0.05, **Table 1**).

# **Correlational Analysis of Behavioral Indicators**

Patients with MCI had significantly poorer performance on the OI test than the NC, and there were significant differences in the OI and MoCA scores between the MCI and NC groups (p < 0.01, **Table 2**). After MoCA score was converted into ranked information, the Pearson correlation test showed that the olfactory function of patients with MCI was poorer than NC, and neuropsychological test results were positively correlated with the olfactory test value (r = 0.682, p < 0.01; **Table 3** and **Figure 1**). In addition, we found that the value of the olfaction test had high specificity for predicting MCI (area under the curve = 0.951; **Figure 2**).

### **Correlational Analysis of Imaging** Indicators

Compared with the NC group, the MCI group showed significantly higher DR and lower FA (p < 0.05; Table 4).





Whole-brain TBSS analysis showed that the areas of lower FA (active area) were primarily localized to areas around the corpus callosum, orbitofrontal gyrus, and left inferior occipital gyrus. However, there was no significant FA difference around the hippocampus (**Figure 3**).

Compared with the NC group, the fiber tracking connection area (red area) in the MCI group was significantly lower (**Figure 4**). In the MCI group, a large number of fibers reached the cerebellum (Cerebelum\_3\_L), insula (Supp\_Motor\_Area\_R), and intraorbital superior frontal gyrus (Frontal\_Mid\_2\_R) (**Figure 5A** blue underline). In the NC group, numerous fibers reached the parahippocampal gyrus (ParaHippocampal\_L), cerebellum (Cerebelum\_6\_R), and fusiform gyrus (Fusiform\_R) (**Figure 5B** red underline). Notably, several connection areas were observed in the MCI group, which were not observed

TABLE 4   Whole-brain DTI analyses.							
	MCI	NC	t	p			
FA	$0.67200 \pm 0.02800$	$0.69100 \pm 0.01600$	-2.814	0.007			
MD	$0.00069 \pm 0.00003$	$0.00068 \pm 0.00002$	1.1230	0.268			
DA	$0.00130 \pm 0.00003$	$0.00130 \pm 0.00004$	-1.139	0.261			
DR	$0.00037 \pm 0.00004$	$0.00035 \pm 0.00002$	2.1110	0.040			

in the NC group, such as the intraorbital superior frontal gyrus (Frontal\_Mid\_2\_R), inferior frontal gyrus of island cap (Frontal\_Inf\_Tri\_R), and olfactory cortex (Olfactory\_L) (**Figure 5A** orange underline). Compared with the NC group, the number and range of fibers reaching the parahippocampal gyrus in the MCI group were significantly lower (**Figures 4**, 5).

In the present study, the main functional areas (hippocampus, bilateral medial temporal lobe, and parahippocampal gyrus) that are responsible for olfactory and cognitive functions were weaker in MCI patients, especially the parahippocampal gyrus and bilateral medial temporal lobe (**Figures 4**, **5**).

### **Correlations Between Behavioral and Imaging Indicators**

The mean FAs of the orbitofrontal gyrus, hippocampus, inferior occipital gyrus, and parahippocampal gyrus were extracted from the ROIs of all subjects, and Pearson correlation analyses were performed between the MoCA, OI scores and the FA values. Compared with the NC group, the OI score was significantly correlated with the FA value of the orbitofrontal gyrus in the MCI group, followed by the inferior occipital gyrus, and there were significant differences (p < 0.05; **Table 5**). However, in our cohort of MCI group, there were no significant differences between the MoCA score and the FA values.



## DISCUSSION

In line with our *a priori* hypothesis, we found that the olfactory ability of MCI patients was impaired overall and was positively correlated with the MoCA score. Using receiver operating characteristic (ROC) analysis, we revealed that the olfactory

test value had high specificity for predicting MCI. Impaired olfactory function was associated with lower general cognitive performance, which was associated with a higher prevalence of MCI. This result suggests that OI is an important marker of cerebral neuropathological changes (Devanand et al., 2015; Palta et al., 2018). Indeed, a meta-analysis reported that olfactory



function is vulnerable to pathological changes in patients with AD and MCI and that olfactory function is impaired in patients with AD more profoundly than in those with MCI (Jung et al., 2019), which indicates that OI may also be a marker of MCI-to-AD transition risk (Wu et al., 2019).

It is well established that the orbitofrontal gyrus serves as the higher olfactory center. The corpus callosum, which serves as a communication channel between the bilateral cerebral hemispheres, connects the frontal lobes of the bilateral cerebral hemispheres. The frontal lobe is the higher brain area and is responsible for a variety of activities, which include smell and emotion. This explains why abnormalities in the structure of the corpus callosum cause damage to nerve pathways projecting to the frontal lobe, which result in changes in sense of smell and episodic memory. Therefore, structural abnormalities of the corpus callosum should also be regarded as a crucial factor that causes olfactory function impairment. Several studies have confirmed that early pathological changes in AD occur in the primary olfactory cortex (Conti et al., 2013; Roberts et al., 2016), which is consistent with our study. Our TBSS results showed that the areas of disruption in the MCI group were located primarily in the corpus callosum, orbitofrontal gyrus, and left occipital lobe. However, the area around the hippocampus was not significantly different between the groups; moreover, there were fewer fibrous connections between brain regions related to olfaction, memory, and cognition. These findings suggested that,

in MCI patients, the microstructure of the orbitofrontal gyrus and corpus callosum was damaged, whereas changes in hippocampal microstructure were not significant. This indicated that white matter damage in regions underlying olfactory function was obvious in MCI patients, whereas white matter damage in areas involved in memory and cognition was not apparent. Taken together, these findings suggest that decline in olfactory function occurs earlier than does cognitive function impairment. The olfactory system was highly connected with entorhinalhippocampal-cortical and amygdala-parasympathetic clusters, which is in line with previous literature (Ubeda-Bañon et al., 2020). Furthermore, results from a pilot study suggested that the reduction in the size of the hippocampus is associated with a loss of OI ability, rather than the loss of memory in relation to early AD (Kjelvik et al., 2014). However, another study reported that olfactory impairment was associated with white matter lesions that were independent of hippocampal atrophy (Heinrich et al., 2018). Our TBSS results of the MCI group indicated that there were no significant alterations in the area around the hippocampus, which is involved in cognitive and memory functions; thus, indicating that changes in hippocampal microstructure in MCI patients were not significant. This further confirms that impairment in olfactory function is superior to memory deficits for predicting cognitive decline.

As shown in a previous investigation, olfactory changes can appear earlier than typical dementia symptoms and inflict

Contrast Name	Degion Labol	Extent	+	MNI Coordinates		
	Region Label	Extent	t-value	x	у (О	z
Positive	Cerebelum_3_L	139986	1.000	-3	-40	-14
	Frontal_Mid_2_R Frontal_Mid_2_R	140 55	1.000 1.000	35 28	8 10	36 45
	Cerebelum_4_5_R	134	0.957	20 19	-38	-2
	Fusiform_R	51	0.957	29	-62	-2
	Lingual_R	43	0.957	12	-70	-3
	Lingual_R	20	0.957	23	-57	-3
	Olfactory_L	145	0.957	-2	25	-3
	Precuneus_R	23	0.957	10	-40	5
	Precuneus_L	67	0.957	1	-50	38
	Frontal_Sup_2_R	111	0.957	16	18	49
	Supp_Motor_Area_R	216	0.957	4	16	52
	Vermis_9	43	0.913	-1	-54	-30
	Fusiform_R	24	0.913	22	-32	-18
	Lingual_R	50	0.913	21	-71	-12
	Frontal_Mid_2_R	50	0.913	24	47	3
	Frontal_Inf_Tri_R	84	0.913	47	40	4
	Calcarine_R	46	0.913	29	-68	7
	Cingulate_Ant_R	56	0.913	14	41	19
	Frontal_Sup_Medial_R	25	0.913	4	54	20
	Frontal_Mid_2_R	39	0.913	42	46	22
	Frontal_Sup_Medial_R	61	0.913	7	60	29
	Frontal_Sup_2_R	27	0.913	24	35	30
	Frontal_Mid_2_R	213	0.913	34	38	33
	Frontal_Sup_2_R	28	0.913	17	42	33
	Frontal_Sup_2_R	20	0.913	24	31	38
(A) B Contrast Name	Frontal_Sup_2_R	59	0.913	25	23	40 ates
B	Frontal_Sup_2_R Region Label	59 Extent		25	23	
B Contrast Name	Region Label	Extent	0.913 t-value	25 MN X	23 I Coordina y	ates z
B	Region Label ParaHippocampal_L	Extent 179823	0.913 t-value 1.000	25 MN x -18	23 I Coordina y -22	ates z -1
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R	Extent 179823 63	0.913 t-value 1.000 1.000	25 MN x -18 48	23 I Coordina y -22 -39	ates z -1, 17
B Contrast Name	Region Label ParaHippocampal_L	Extent 179823	0.913 t-value 1.000	25 MN x -18	23 I Coordina y -22	ates z -1, 17
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R	Extent 179823 63 171	0.913 t-value 1.000 1.000	25 MN x -18 48 20	23 I Coordina y -22 -39	ates 
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R	Extent 179823 63 171 21	0.913 t-value 1.000 1.000 0.955 0.955	25 MN -18 48 20 28	23 I Coordina y -22 -39 -69 -49	ates 
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R	Extent 179823 63 171 21 79	0.913 t-value 1.000 1.000 0.955 0.955 0.955	25 MN -18 48 20 28 33	23 I Coordina -22 -39 -69 -49 -57	ates 1; 1; 1; 1; 1; 1;
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L	Extent 179823 63 171 21 79 35	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19	23 I Coordina y -22 -39 -69 -49 -57 -55	ates 2 -11 17 -11 -11 -11 -11 -7
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L	Extent 179823 63 171 21 79 35 21	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26	23 I Coordina y -22 -39 -69 -49 -57 -55 -69	ates -11 17 -11 -11 -11 -7 -7 -4
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R	Extent 179823 63 171 21 79 35 21 26	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38	23 I Coordin y -22 -39 -69 -49 -57 -55 -69 13	ates -11 17 -11 -11 -11 -7 -7 -4 2
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R	Extent 179823 63 171 21 79 35 21 26 29	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26	ates 
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R	Extent 179823 63 171 21 79 35 21 26 29 22	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7	23 I Coordina -22 -39 -69 -49 -57 -55 -69 13 -26 -74	ates 2 -11 17 -11 -11 -11 -7 -4 2 5 15
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L	Extent 179823 63 171 21 79 35 21 26 29 22 59	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24	ates 2 -11 17 -11 -11 -7 -4 2 5 15 24
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R	Extent 179823 63 171 21 79 35 21 26 29 22 59 28	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59	z z -1; 17; -1; -1; -1; -1; -1; -1; -1; -2; 5; 15; 22; 28;
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R	Extent 179823 63 171 21 79 35 21 26 29 22 59 22 59 28 31	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 8 44 7 -3 12 20	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83	2 -1 17 -1 -1 -1 -7 -7 -2 2 5 5 1 8 1 8 2 2 2 2 8 4
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R Cingulate_Mid_R	Extent 179823 63 171 21 79 35 21 26 29 22 59 22 59 28 31 75	0.913 t-value 1.000 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12 20 17	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83 -35	z z -18 177 -19 -19 -19 -19 -19 -77 -4 2 2 5 195 24 2 2 2 2 2 2 2 2 2 2 2 2 4 1 4 2 4 1 4 8 4 1 4 8 4 1 2 4 2 2 2 2 8 4 1 2 4 1 7 7 1 7 7 7 1 7 7 7 7 7 7 7 7 7 7 7
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R Cingulate_Mid_R Fusiform_L	Extent 179823 63 171 21 79 35 21 26 29 22 59 22 59 28 31 75 73	0.913 t-value 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12 20 17 -30	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83 -35 -72	z z -1; -1; -1; -1; -1; -1; -1; -7; -4 2 2 5 5 15; 15; 24 24 24; 41 48; -1;
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R Cingulate_Mid_R Fusiform_L Insula_L	Extent 179823 63 171 21 79 35 21 26 29 22 59 28 31 75 73 21	0.913 t-value 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12 20 17	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83 -35 -72 6	z -1 -1 -1 -1 -1 -1 -7 -2 2 5 5 5 5 5 1 { 2 2 2 2 2 2 2 4 4 4 4 4 4 4 4 4 5 -7 -7 -2 -2 -2 -2 -2 -2 -2 -1 -1 7 7 -1 -1 -1 -7 -1 -1 -7 -1 -1 -7 -7 -1 -1 -7 -7 -1 -7 -7 -2 -2 -2 -1 -1 -7 -7 -2 -2 -2 -2 -1 -7 -7 -7 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R Cingulate_Mid_R Fusiform_L	Extent 179823 63 171 21 79 35 21 26 29 22 59 22 59 28 31 75 73	0.913 t-value 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12 20 17 -30	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83 -35 -72	z z -1; 17, -1; -1; -1; -1; -1; -1; -1; -1; -1; -1;
B Contrast Name	Region Label ParaHippocampal_L Temporal_Sup_R Cerebelum_6_R Fusiform_R Fusiform_R Lingual_L Lingual_L Insula_R Temporal_Sup_R Calcarine_R Cingulate_Ant_L Precuneus_R Cuneus_R Cingulate_Mid_R Fusiform_L Insula_L	Extent 179823 63 171 21 79 35 21 26 29 22 59 28 31 75 73 21	0.913 t-value 1.000 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955	25 MN -18 48 20 28 33 -19 -26 38 44 7 -3 12 20 17 -30 -35	23 I Coordina y -22 -39 -69 -49 -57 -55 -69 13 -26 -74 24 -59 -83 -35 -72 6	z -1; -1; -1; -1; -1; -1; -7; -4 2 5 5 5 5 15; 22 28; 41; 42; 41; 48; -1; -6;

FIGURE 5 | Statistic map of the fiber probability tracking. (A) Statistic map of the fiber probability tracking in the MCI group. Blue underline is on behalf of the areas which a large number of fibers mainly reached in the MCI group. Orange underline is on behalf of some areas which can be observed in the MCI group, but can't be observed in the NC group. (B) Statistic map of the fiber probability tracking in the NCI group. Red underline is on behalf of the areas which a large number of fibers mainly reached in the NC group.

greater cognitive impairment (Josefsson et al., 2017); however, the underlying mechanism and pathology remain unclear. Therefore, we speculate that olfaction impairment is a foremost outcome of the pathological changes in these areas, which suggests that changes in olfactory ability lead to pathological changes in these areas, which cause alterations in cognitive function. In addition,

	Orbitofrontal gyrus		Hippocampus		Inferior occipital gyrus		Parahippocampal gyrus	
	p	r	p	r	p	r	p	r
OI score	<0.001	0.5360	0.049	0.2920	0.001	0.4470	0.415	-0.123
MoCA score	0.050	0.2910	0.720	0.0540	0.101	0.2450	0.134	-0.273

TABLE 5 | Correlation between behavioral indicators and FA values of the ROIs.

our findings indicated that fibrous connections in several brain regions, such as the entorhinal cortex, were higher in patients with MCI, which is suggestive of a compensatory mechanism of the olfactory pathway. Thus, we speculate that olfactory training may be useful for improving cognition and may contribute to the prevention of various neurodegenerative diseases. In our traditional perception, the olfactory decline observed in aging may seem irreversible, but emerging evidence suggested that olfactory function may be trained, and olfactory training even has positive effects on cognitive function (Birte-Antina et al., 2018). Indeed, if olfactory training can lead to cognitive benefits, what are the mechanisms? One study found that olfactory training led to increased thickness not only in key olfactory structures but also in fronto-temporal areas outside of the olfactory cortex (Al Ain et al., 2019). A similar study showed that functional brain activity changes in a fronto-parietal network associated with higher cognitive abilities under odor identification training (Fournel et al., 2017). Above findings suggested that intensive olfactory training can improve olfactory function and that this improvement is associated with changes in the structure of olfactory processing areas of the brain. It indicated that olfactory training may give a positive future for improvement of cognition.

Based on the principle of TBSS (Smith et al., 2006), abnormal areas detected in TBSS analyses are those areas that have a significantly lower FA value, which indicates that nerve fibers in these areas have reduced integrity and a limited ability for water molecules to diffuse in the same direction. In our study, we found that the orbitofrontal gyrus had a significantly lower FA value in MCI patients compared with NCs, which also correlated with the olfactory score. However, our imaging findings revealed no correlation between the MoCA score and FA value. One study reported that the MoCA score positively correlated with the FA value of the corpus callosum (Mascalchi et al., 2019). We speculate that the reason for this discrepancy is the susceptibility of the experimental results to bias due to our small sample size.

Most previous studies of AD and MCI patients assessed whole-brain white matter, which included both superficial and deep white matter. Recently, one study evaluated only the superficial white matter and found that microstructural changes in superficial white matter are related to clinical symptoms of AD (Bigham et al., 2020). Therefore, we suggest that microstructural changes in the hippocampus may be detected by exploring the superficial white matter. However, further research investigating superficial white matter is needed to ascertain the precise mechanisms of OI dysfunction.

This study has several limitations. Firstly, we used a relatively small sample size, which may have prevented the detection of biological associations. Nevertheless, we were still able to reveal significant differences. Studying a larger group of patients will likely allow further details to be uncovered. Secondly, because the study used a cross-sectional design, we could not infer whether the changes were due to progression to AD. Thirdly, we used the MoCA to diagnose MCI, because there is currently no specific diagnostic tool based on pathological or molecular imaging assessments. However, the MoCA is only to be a screening tool, it is inaccurate especially in cases who refuse to answer survey questions of the MoCA. Hence, in this community cohort, the predictive accuracy of the MoCA for cognitive decline was moderate, which suggested that the MoCA may need to be combined with other measures to improve predictive power.

Studies on MCI are still limited for preventing progression to dementia. The most valuable finding of our study is that the decline in olfactory function may occur earlier than impairment of cognitive function, which suggests that OI is a significant and useful indicator of neuropathological changes and an effective marker for the development of cognitive decline and dementia.

### CONCLUSION

In summary, the impairment of olfactory function was superior to memory deficits for predicting cognitive decline in cognitively intact participants. We revealed that olfactory function tests are a useful screening tool for cognitive decline in older adults. Moreover, this tool can be used to screen for cognitive decline before the onset of other clinical symptoms of dementia, which will help to reduce delayed and underdiagnoses of MCI and dementia. Taken together, more attention should be given to those with olfactory disorders, because of the associated higher risk of cognitive decline.

### PERMISSION TO REUSE AND COPYRIGHT

We declare that all figures, tables, and images will be published under a Creative Commons CC-BY license. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Review Committee of Shanghai East Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

### **AUTHOR CONTRIBUTIONS**

YS, BJ, HQ, SH, and YZ helped to collect the behavioral and imaging data. YS wrote the first draft of the manuscript. ZW and BJ helped in MRI data analysis. YZ, QX and GL supervised the initial drafting, and critically revised the manuscript. QX analyzed the article and critically revised the manuscript. All

### REFERENCES

- Al Ain, S., Poupon, D., Hetu, S., Mercier, N., Steffener, J., and Frasnelli, J. (2019). Smell training improves olfactory function and alters brain structure. *Neuroimage* 189, 45–54. doi: 10.1016/j.neuroimage.2019.01.008
- Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.03.008
- Ashwin, C., Chapman, E., Howells, J., Rhydderch, D., Walker, I., and Baron-Cohen, S. (2014). Enhanced olfactory sensitivity in autism spectrum conditions. *Mol. Autism* 5:53. doi: 10.1186/2040-2392-5-53
- Bigham, B., Zamanpour, S. A., Zemorshidi, F., Boroumand, F., and Zare, H. (2020). Alzheimer's disease neuroimaging initiative. Identification of superficial white matter abnormalities in Alzheimer's disease and mild cognitive impairment using diffusion tensor imaging. J. Alzheimers Dis. Rep. 4, 49–59. doi: 10.3233/ ADR-190149
- Birte-Antina, W., Ilona, C., Antje, H., and Thomas, H. (2018). Olfactory training with older people. *Int. J. Geriatr. Psychiatry* 33, 212–220. doi: 10.1002/gps.4725
- Conti, M. Z., Vicini-Chilovi, B., Riva, M., Zanetti, M., Liberini, P., Padovani, A., et al. (2013). Odor identification deficit predicts clinical conversion from mild cognitive impairment to dementia due to Alzheimer's disease. Arch. Clin. Neuropsychol. 28, 391–399. doi: 10.1093/arclin/act032
- Davidson, T. M., Freed, C., Healy, M. P., and Murphy, C. (1998). Rapid clinical evaluation of anosmia in children: the alcohol sniff test. Ann. N. Y. Acad. Sci. 855, 787–792. doi: 10.1111/j.1749-6632.1998.tb10659.x
- Demir, S., Sizer, B., Gul, A., and Topcu, I. (2021). Culturally modified olfactory test adapted to East-Turkey: a comparison with Sniffin' Sticks. *Int. J. Clin. Pract.* 75:e14458. doi: 10.1111/ijcp.14458
- Devanand, D. P. (2016). Olfactory identification deficits, cognitive decline, and dementia in older adults. Am. J. Geriatr. Psychiatry 24, 1151–1157. doi: 10.1016/ j.jagp.2016.08.010
- Devanand, D. P., Lee, S., Manly, J., Andrews, H., Schupf, N., Doty, R. L., et al. (2015). Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. *Neurology* 84, 182–189. doi: 10.1212/WNL. 000000000001132
- Fournel, A., Sezille, C., Licon, C. C., Sinding, C., Gerber, J., Ferdenzi, C., et al. (2017). Learning to name smells increases activity in heteromodal semantic areas. *Hum. Brain Mapp.* 38, 5958–5969. doi: 10.1002/hbm.23801
- Georgiopoulos, C., Warntjes, M., Dizdar, N., Zachrisson, H., Engström, M., Haller, S., et al. (2017). Olfactory impairment in Parkinson's disease studied with diffusion tensor and magnetization transfer imaging. *J. Parkinsons Dis.* 7, 301–311. doi: 10.3233/JPD-161060
- Heinrich, J., Vidal, J. S., Simon, A., Rigaud, A. S., Hanon, O., Epelbaum, J., et al. (2018). Relationships between lower olfaction and brain white matter lesions

authors read and approved the final manuscript and contributed to the article conception.

### FUNDING

This project was supported by the National Natural Science Foundation of China (Grant No. 81301200), and the Science and Technology Commission of Shanghai Municipality (Grant Nos. 19411951400 and 20Y11911700).

### ACKNOWLEDGMENTS

We thank all the participants for their cooperation during this study.

in elderly subjects with mild cognitive impairment. J. Alzheimers Dis. 61, 1133-1141. doi: 10.3233/JAD-170378

- Josefsson, M., Larsson, M., Nordin, S., Adolfsson, R., and Olofsson, J. (2017). APOE-€4 effects on longitudinal decline in olfactory and non-olfactory cognitive abilities in middle-aged and old adults. *Sci. Rep.* 7:1286. doi: 10.1038/ s41598-017-01508-7
- Jung, H. J., Shin, I. S., and Lee, J. E. (2019). Olfactory function in mild cognitive impairment and Alzheimer's disease: a meta-analysis. *Laryngoscope* 129, 362– 369. doi: 10.1002/lary.27399
- Kim, S. M., Kim, H. R., Min, H. J., Kim, K. S., Ga, H., Lee, S. H., et al. (2020). Impaired odor identification of culturally familiar odorants associated with dementia in South Korean older adults. *Int. J. Environ. Res. Public Health* 17:8441. doi: 10.3390/ijerph17228441
- Kim, S. M., Kim, H. R., Min, H. J., Kim, K. S., Jin, J. C., and Han, D. H. (2021). A novel olfactory threshold test for screening cognitive decline among elderly people. *PLoS One* 16:e0254357. doi: 10.1371/journal.pone.0254357
- Kjelvik, G., Evensmoen, H. R., Hummel, T., Engedal, K., Selbæk, G., Saltvedt, I., et al. (2020). The human brain representation of odor identification in amnestic mild cognitive impairment and Alzheimer's dementia of mild degree. *Front. Neurol.* 11:607566. doi: 10.3389/fneur.2020.607566
- Kjelvik, G., Saltvedt, I., White, L. R., Stenumgård, P., Sletvold, O., Engedal, K., et al. (2014). The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer's disease. *BMC Neurol.* 14:168. doi: 10.1186/s12883-014-0168-1
- Knight, M. J., Wearn, A., Coulthard, E., and Kauppinen, R. A. (2019). T2 relaxometry and diffusion tensor indices of the hippocampus and entorhinal cortex improve sensitivity and specificity of MRI to detect amnestic mild cognitive impairment and Alzheimer's disease dementia. J. Magn. Reson. Imaging 49, 445–455. doi: 10.1002/jmri.26195
- Lane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease. *Eur. J. Neurol.* 25, 59–70. doi: 10.1111/ene.13439
- Li, Q., Wang, J., Liu, J., Wang, Y., and Li, K. (2021). Magnetic resonance imaging measurement of entorhinal cortex in the diagnosis and differential diagnosis of mild cognitive impairment and Alzheimer's disease. *Brain Sci.* 11:1129. doi: 10.3390/brainsci11091129
- Lu, J., Li, D., Li, F., Zhou, A., Wang, F., Zuo, X., et al. (2011). Montreal cognitive assessment in detecting cognitive impairment in chinese elderly individuals: a population-based study. J. Geriatr. Psychiatry Neurol. 24, 184–190. doi: 10.1177/ 0891988711422528
- Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., et al. (2018). Olfactory dysfunction in neurodegenerative diseases. *Curr. Allergy Asthma Rep.* 18:42. doi: 10.1007/s11882-018-0796-4
- Mascalchi, M., Salvadori, E., Toschi, N., Giannelli, M., Orsolini, S., Ciulli, S., et al. (2019). DTI-derived indexes of brain WM correlate with cognitive performance in vascular MCI and small-vessel disease. A TBSS study. *Brain Imaging Behav.* 13, 594–602. doi: 10.1007/s11682-018-9873-5

- Palta, P., Chen, H., Deal, J. A., Sharrett, A. R., Gross, A., Knopman, D., et al. (2018). Olfactory function and neurocognitive outcomes in old age: the atherosclerosis risk in communities neurocognitive study. *Alzheimers Dement.* 14, 1015–1021. doi: 10.1016/j.jalz.2018.02.019
- Roberts, R. O., Christianson, T. J., Kremers, W. K., Mielke, M. M., Machulda, M. M., Vassilaki, M., et al. (2016). Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. *JAMA Neurol.* 73, 93–101. doi: 10.1001/jamaneurol.2015. 2952
- Shu, H., Gu, L., Yang, P., Lucas, M. V., Gao, L., Zhang, H., et al. (2021). Disturbed temporal dynamics of episodic retrieval activity with preserved spatial activity pattern in amnestic mild cognitive impairment: a simultaneous EEG-fMRI study. *Neuroimage Clin.* 30:102572. doi: 10.1016/j.nicl.2021.102572
- Smith, S. M., Jenkinson, M., Johansen-Berg, H., Rueckert, D., Nichols, T. E., Mackay, C. E., et al. (2006). Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *Neuroimage* 31, 1487–1505. doi: 10.1016/j. neuroimage.2006.02.024
- Tae, W. S., Ham, B. J., Pyun, S. B., Kang, S. H., and Kim, B. J. (2018). Current clinical applications of diffusion-tensor imaging in neurological disorders. J. Clin. Neurol. 14, 129–140. doi: 10.3988/jcn.2018.14.2.129
- Ubeda-Bañon, I., Saiz-Sanchez, D., Flores-Cuadrado, A., Rioja-Corroto, E., Gonzalez-Rodriguez, M., Villar-Conde, S., et al. (2020). The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases. *Transl. Neurodegener*. 9:22. doi: 10.1186/s40035-020-00200-7
- Woodward, M. R., Dwyer, M. G., Bergsland, N., Hagemeier, J., Zivadinov, R., Benedict, R. H., et al. (2017). Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease. *Psychiatry Res. Neuroimaging* 266, 90–95. doi: 10.1016/j.pscychresns.2017.06.004

- Wu, X., Geng, Z., Zhou, S., Bai, T., Wei, L., and Ji, G. (2019). Brain structural correlates of odor identification in mild cognitive impairment and Alzheimer's disease revealed by magnetic resonance imaging and a chinese olfactory identification test. *Front. Neurosci.* 13:842. doi: 10.3389/fnins.2019.00842
- Yoo, H. S., Jeon, S., Chung, S. J., Yun, M., Lee, P. H., Sohn, Y. H., et al. (2018). Olfactory dysfunction in Alzheimer's disease- and lewy body-related cognitive impairment. *Alzheimers Dement.* 14, 1243–1252. doi: 10.1016/j.jalz.2018.05.010
- Zhao, F., Wang, X., Zariwala, H. A., Uslaner, J. M., Houghton, A. K., Evelhoch, J. L., et al. (2016). FMRI study of olfaction in the olfactory bulb and high olfactory structures of rats: insight into their roles in habituation. *Neuroimage* 127, 445–455. doi: 10.1016/j.neuroimage.2015.10.080

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Shao, Wang, Ji, Qi, Hao, Li, Zhang and Xi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.